Protein Biomarkers for Traumatic and Ischemic Brain Injury: From Bench to Bedside

Translational Stroke Research

Volumn 2, Issue 4, 2011, Pages 455-462

  Zhang, Zhiqun ^a   Mondello, Stefania ^a   Kobeissy, Firas ^a,b   Rubenstein, Richard ^a,c   Streeter, Jackson ^a   Hayes, Ronald L ^a,b   Wang, Kevin K W ^a,b,d  

^a BANYAN BIOMARKERS INC   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Downstate Health Sciences University   (United States)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Biomarkers; Brain injury; Cell death proteolysis

Indexed keywords

BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN;

BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; GENOMICS; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK; TRAUMATIC BRAIN INJURY;

EID: 83355177952     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-011-0137-6     Document Type: Review

References (78)

1. Saatman KE, et al. Classification of traumatic brain injury for targeted therapies. J Neurotrauma. 2008; 25(7): 719-38.
2. Wang KK, et al. Neuroprotection targets after traumatic brain injury. Curr Opin Neurol. 2006; 19(6): 514-9.
3. Svetlov SI, et al. Biomarkers of blast-induced neurotrauma: profiling molecular and cellular mechanisms of blast brain injury. J Neurotrauma. 2009; 26(6): 913-21.
4. Kobeissy FH, et al. Neuroproteomics and systems biology-based discovery of protein biomarkers for traumatic brain injury and clinical validation. Prot Clin Appl. 2008; 2(10-11): 1467-83.
5. Wang KK, et al. Proteomic identification of biomarkers of traumatic brain injury. Expert Rev Proteomics. 2005; 2(4): 603-14.
6. Haskins WE, et al. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry. J Neurotrauma. 2005; 22(6): 629-44.
7. Papa L, Robinson GMW, Oli MW, Robicsek SA, Gabrielli A, Robertson CS, Wang KKW, Hayes RL. Use of biomarkers for diagnosis and management of traumatic brain injury patients. Expert Opin Med Diagn. 2008; 2(8): 1-9.
8. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease. Am Heart J. 2010; 160(4): 583-94.
9. Velagaleti RS, et al. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol. 2010; 30(11): 2283-8.
10. Singh D, et al. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010; 11: 77.
11. Denslow N, et al. Application of proteomics technology to the field of neurotrauma. J Neurotrauma. 2003; 20(5): 401-7.
12. Pelinka LE, et al. Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock. 2005; 24(2): 119-23.
13. Berger RP, et al. Serum biomarker concentrations and outcome after pediatric traumatic brain injury. J Neurotrauma. 2007; 24(12): 1793-801.
14. Berger RP, et al. Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics. 2006; 117(2): 325-32.
15. Johnsson P, et al. Neuron-specific enolase increases in plasma during and immediately after extracorporeal circulation. Ann Thorac Surg. 2000; 69(3): 750-4.
16. Berger RP, et al. Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg. 2005; 103(1 Suppl): 61-8.
17. Ingebrigtsen T, Romner B. Biochemical serum markers for brain damage: a short review with emphasis on clinical utility in mild head injury. Restor Neurol Neurosci. 2003; 21(3-4): 171-6.
18. Papa L, et al. Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med. 2010; 38(1): 138-44.
19. Dambinova SA, et al. Blood test detecting autoantibodies to N-methyl-d-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003; 49(10): 1752-62.
20. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005; 233(1-2): 183-98.
21. Petzold A, Shaw G. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods. 2007; 319(1-2): 34-40.
22. Kobeissy FH, et al. Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Prot. 2006; 5(10): 1887-98.
23. Ottens AK, et al. Neuroproteomics: a biochemical means to discriminate the extent and modality of brain injury. J Neurotrauma. 2010; 27(10): 1837-52.
24. Yao C, et al. P43/pro-EMAPII: a potential biomarker for discriminating traumatic versus ischemic brain injury. J Neurotrauma. 2009; 26(8): 1295-305.
25. Yao X, Liu J, McCabe JT. Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model. J Neurochem. 2008; 104(2): 353-63.
26. Liu MC, et al. Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis. Biochem J. 2006; 394(Pt 3): 715-25.
27. Brophy GM, et al. alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 2009; 26(4): 471-9.
28. Lewis SB, et al. Identification and preliminary characterization of ubiquitin C terminal hydrolase 1 (UCHL1) as a biomarker of neuronal loss in aneurysmal subarachnoid hemorrhage. J Neurosci Res. 2010; 88(7): 1475-84.
29. Svetlov SI, et al. Morphologic and biochemical characterization of brain injury in a model of controlled blast overpressure exposure. J Trauma. 2010; 69(4): 795-804.
30. Serbest G, et al. Temporal profiles of cytoskeletal protein loss following traumatic axonal injury in mice. Neurochem Res. 2007; 32(12): 2006-14.
31. Siman R, et al. A panel of neuron-enriched proteins as markers for traumatic brain injury in humans. J Neurotrauma. 2009; 26(11): 1867-77.
32. Ehrenreich H, et al. Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med. 2011. doi: 10. 2119/molmed. 2011. 00259.
33. Allard L, et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem. 2005; 51(11): 2043-51.
34. Foerch C, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke. 2007; 38(9): 2491-5.
35. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med. 2009; 7: 97.
36. Reynolds MA, et al. Early biomarkers of stroke. Clin Chem. 2003; 49(10): 1733-9.
37. Grant SG. Systems biology in neuroscience: bridging genes to cognition. Curr Opin Neurobiol. 2003; 13(5): 577-82.
38. Grant SG, Blackstock WP. Proteomics in neuroscience: from protein to network. J Neurosci. 2001; 21(21): 8315-8.
39. Chen SS, et al. Bioinformatics for traumatic brain injury: proteimic data mining. In: Pardalos PM, Boginski VL, Vazacopoulos A, editors. Data mining in biomedicine. New York: Springer; 2007. p. 1-26.
40. Beltrao P, Kiel C, Serrano L. Structures in systems biology. Curr Opin Struct Biol. 2007; 17(3): 378-84.
41. Narayan RK, et al. Clinical trials in head injury. J Neurotrauma. 2002; 19(5): 503-57.
42. Flynn RW, MacWalter RS, Doney AS. The cost of cerebral ischaemia. Neuropharmacology. 2008; 55(3): 250-6.
43. Zaleska MM, et al. The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology. 2009; 56(2): 329-41.
44. Donnan GA, et al. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol. 2011; 7(7): 400-9.
45. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke. 2008; 39(10): 2902-9.
46. Kavalci C, et al. Value of biomarker-based diagnostic test in differential diagnosis of hemorrhagic-ischemic stroke. Bratisl Lek Listy. 2011; 112(7): 398-401.
47. Herrmann M, et al. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein. Stroke. 2000; 31(11): 2670-7.
48. Datta A, Jingru Q, Khor TH, Teo MT, Heese K, Sze SK. Quantitative neuroproteomics of an in vivo rodent model of focal cerebral ischemia reperfusion injury reveals a temporal regulation of novel pathophysiological molecular markers. J Proteome Res. 2011; 10(11): 5199-213.
49. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke. 2003; 28(10): 1956-60.
50. Raabe A, Grolms C, Seifert V. Serum markers of brain damage and outcome prediction in patients after severe head injury. Br J Neurosurg. 1999; 13: 56-9.
51. Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE. Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma. 2002; 17(8): 641-7.
52. Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, et al. Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci. 2003; 21(3-4): 109-21.
53. Blyth BJ, Farhavar A, Gee C, Hawthorn B, He H, Nayak A, Stöcklein V, Bazarian JJ. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma. 2009; 26(9): 1497-1507.
54. Yamazaki Y, Yada K, Morii S, Kitahara T, Ohwada T. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury. Surg Neurol. 1995; 43(3): 267-70.
55. Ross SA, Cunningham RT, Johnston CF, Rowlands BJ. Neuron-specific enolase as an aid to outcome prediction in head injury. Br J Neurosurg. 1996; 10(5): 471-6.
56. Pelinka LE, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, Raabe A. Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma. 2004a; 57(5): 1006-12.
57. Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma. 2004b; 21(11): 1553-61.
58. Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, et al. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology. 2004; 62(8): 1303-10.
59. Lumpkins KM, Bochicchio GV, Keledjian K, Simard JM, McCunn M. Scalea T. Glial fibrillary acidic protein is highly correlated with brain injury. J Trauma. 2008; 65(4): 778-84.
60. Dvorak F, Haberer I, Sitzer M, Foerch C. Characterisation of the diagnostic window of serum glial fibrillary acidic protein for the differentiation of intracerebral haemorrhage and ischaemic stroke. Cerebrovasc Dis. 2009; 27(1): 37-41.
61. Papa L, Lewis L, Falk J, Zhang Z, Silvestri S, Giordano P, et al. Glial fibrillary acidic protein breakdown product as a novel serum biomarker for mild and moderate traumatic brain Injury. Ann Emerg Med. (in press).
62. Mondello S, Papa L, Buki A, Bullock MR, Czeiter E, Tortella FC, Wang KK, Hayes RL. Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care. 2011; 15(3): R156.
63. Pike BR, Flint J, Dutta S, Johnson E, Wang KKW, Hayes RL. Accumulation of non-erythroid αII-spectrin and calpain-cleaved αII-spectrin breakdown products in cerebrospinal fluid after TBI in rats. J Neurochem. 2001; 78(6): 1297-306.
64. Ringger NC, O'Steen BE, Brabham JG, Siler X, Pineda J, Wang KKW, Hayes RL. A novel marker for traumatic brain injury: CSF αII-spectrin breakdown product levels. J Neurotrauma. 2004; 21(10): 1443-56.
65. Siman R, Zhang C, Roberts VL, Pitts-Kiefer A, Neumar RW. Novel surrogate markers for acute brain damage: cerebrospinal fluid levels corrrelate with severity of ischemic neurodegeneration in the rat. J Cereb Blood Flow Metab. 2005; 25(11): 1433-44.
66. Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL. Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis. 2004; 16(2): 311-20.
67. Pineda JA, Lewis SB, Valadka SB, Papa L, Hannay HJ, Heaton S, et al. Clinical significance of αII-spectrin breakdown products in CSF after severe TBI. J Neurotrauma. 2007; 24(2): 354-66.
68. Mondello S, Robicsek SA, Gabrielli A, Tepas J, Robinson C, Buki A, et al. αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. 2010; 27(7): 1203-13.
69. Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, Zuccarello M. C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome. Brain Res. 2002; 947(1): 131-9.
70. Shaw GJ, Jauch EC, Zemlan FP. Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury. Ann Emerg Med. 2002; 39(3): 254-7.
71. Maier B, Laurer HL, Rose S, Buurman WA, Marzi I. Physiological levels of pro- and anti-inflammatory mediators in cerebrospinal fluid and plasma: a normative study. J Neurotrauma. 2005; 22(7): 822-35.
72. Chiaretti A, Antonelli A, Mastrangelo A, Pezzotti P, Tortorolo L, Tosi F, Genovese O. Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury. J Neurotrauma. 2008; 25(3): 225-34.
73. Folkersma H, Brevé JJ, Tilders FJ, Cherian L, Robertson CS, Vandertop WP. Cerebral microdialysis of interleukin (IL)-1beta and IL-6: extraction efficiency and production in the acute phase after severe traumatic brain injury in rats. Acta Neurochir (Wien). 2008; 150(12): 1277-84.
74. Pelsers MM, Glatz JF. Detection of brain injury by fatty acid-binding proteins. Clin Chem Lab Med. 2005; 43(8): 802-9.
75. Pelsers MM, Hanhoff T, van der Voort D, Arts B, Peters M, Ponds R, et al. Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem. 2004; 50(9): 1568-75.
76. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005; 233(1-2): 183-98.
77. Norgren N, Sundström P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004; 63(9): 1586-90.
78. Liu MC, Akinyi L, Larner SF, Oli M, Zheng WR, Kobeissy F, et al. Ubiquitin C-terminal hydrolase-L1 as a novel biomarker for ischemic and traumatic brain injury in rats. Euro J Neurosci. 2010; 31(4): 722-32.